Novo Nordisk semaglutide (Ozempic/Wegovy) revenue

Novo Nordisk's semaglutide revenue and WNBA average game attendance have, between 2018 and 2024, risen together at a correlation of 0.952. The pairing — one a metabolic intervention, one a sports attendance story — is almost inspirationally unrelated. Both represent, at some level, a country finally paying attention to something it had previously ignored.

Novo Nordisk's semaglutide revenue exploded from near zero in 2018 to over $25 billion by 2024 as Ozempic and Wegovy crossed into weight loss and metabolic health. WNBA average game attendance grew from about 6,700 in 2018 to over 9,800 by 2024, propelled by the arrival of generational talents like A'ja Wilson and Caitlin Clark, plus growing investment in women's basketball broadcast and marketing infrastructure. Both trends reflect the same cultural moment of previously-underinvested categories finally getting the attention and resources they needed. The pharmaceutical breakthrough and the sports league both broke through in the same six years.

Six years of two lines rising together can describe two previously-overlooked categories hitting critical mass simultaneously. The injection and the tip-off are not connected. The timing, however, is.